BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing
BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors.
"With one of the industry's leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynam
